Background: Disseminated nontuberculous mycobacteria (NTM) infections occur mostly in immunocompromised patients. Therefore, it is difficult to diagnose disseminated NTM infections in patients without history of immunocompromised diseases or using immunosuppressant. Patients with anti-interferon-γ (IFN-γ) autoantibodies are vulnerable to intracellular infections, such as disseminated NTM. Currently, there is no widely used and efficient technique for the detection of anti-IFN-γ autoantibodies. Herein, we report a case of an apparently healthy patient with disseminated Mycobacterium avium complex (MAC) infection who tested positive for anti-IFN-γ autoantibodies.
Background
Nontuberculous mycobacteria (NTM) are a group of microorganisms ubiquitous in the environment. There are more than 160 species of NTM, of which at least 50 have been associated with pulmonary infectious disease. Unlike Mycobacterium tuberculosis, human-to-human transmission of NTM is not common. It is more difficult to treat NTM than M. tuberculosis due to drug resistance, and the treatment period usually lasts more than 12 months [1] . Although several studies have revealed NTM infections in both immunocompetent and immunocompromised patients, disseminated NTM infection is usually among immunocompromised patients such as people using long-term immunosuppressants or patients with human immunodeficiency virus (HIV) infection, particularly in those with CD4 counts below 50 cells/μL [2] . Interferon-γ (IFN-γ), which is secreted by natural killer (NK) cells and T cells, plays a critical role in cellular immunity. Previous studies have suggested that IFN-γ autoantibodies may play an important Institute of Emergency and Critical Care medicine and Faculty of Medicine, Medicine, School of Medicine, National Yang-Ming University, No. 201, Sec. 2, Shih-Pai Rd., Beitou District, Taipei 11217, Taiwan Full list of author information is available at the end of the article role in refractory and recurrent disseminated NTM infections [3] . Therefore, we present a case of a previously healthy patient with disseminated MAC infection who tested positive for anti-IFN-γ autoantibodies.
Case presentation
A 64-year-old Asian male patient presented to the emergency department with complaints of progressive chest pain for about 6 months and weight loss. A review of the patient's medical records revealed a prior history of benign prostatic hyperplasia and hypertension. There was no apparent history of alcohol consumption, smoking, illicit drugs herbs, or immunosuppressants.
A bulging mass was found in his anterior chest wall ( Fig. 1 ). Notable laboratory findings included a white blood cell count of 11,400/μL and a C-reactive protein level of 8 mg/L. Chest computed tomography revealed an osteolytic lesion with a soft tissue component at the sternum mediastinal lymphadenopathy ( Fig. 2, arrow) , and a lung mass in the right lower lobe (RLL) ( Fig. 3 , arrowhead). Considering the possibility of lung cancer with mediastinal lymphadenopathy and bone metastasis, a sonography-guided biopsy was performed for the osteolytic lesion over the sternum. The pathological report indicated a focal granulomatous inflammation and necrosis without malignant cells. However, Ziehl-Neelsen staining was positive. Tissue culture and two sets of sputum all tested positive for Mycobacterium avium complex (MAC). Thus, MAC infection was suspected. Positive result of anti-IFN-γ autoantibodies was noted compared with control samples (Fig. 4 ). Although the patient did not report any prior history of immunosuppressant use and there was no serological evidence of HIV infection or autoimmune diseases, he was considered to be at risk of disseminated NTM infection due to a positive test result for anti-IFN-γ autoantibodies.
Hence, the patient was prescribed with oral form of clarithromycin 500 mg twice daily, oral form of rifabutin 300 mg daily, oral form of ethambutol 15 mg/kg daily, and intravenous amikacin 15 mg/kg three times a week for 3 months followed by oral form of clarithromycin 500 mg twice daily, oral form of rifabutin 300 mg daily, and oral form of ethambutol 300 mg daily for another 9 months. The lesions over the RLL and sternum diminished gradually following the treatment (Figs. 5 and 6).
Discussion and conclusions
Disseminated NTM NTM are a group of microbes that are highly prevalent in the environment. Infections resulting from NTM have received more attention recently, especially among patients with chronic renal disease, malignancy, autoimmune disease, and acquired immune deficiency syndrome (AIDS). Nonetheless, the diagnosis of NTM infection can be challenging and biopsy is sometimes necessary to confirm the diagnosis of NTM infection [5] . Lymph nodes are the primary organs that are involved in an NTM infection, followed by osteoarticular system, bone, lung, and skin [4, 6] . Unlike M. tuberculosis (TB), NTM infection does not show human-to-human transmission. Moreover, NTM infection is more difficult to treat compared with infections due to TB because of the high level of resistance to available antimicrobial agents. For example, nearly all NTM species show resistance to pyrazinamide, which is one of mainstay anti-TB drugs. Furthermore, in the case of severe or disseminated NTM, the BTS guidelines recommend intravenous antibiotics, such as amikacin, for at least 3 months. Intravenous antibiotics using may lead to prolong hospitalization stay and influence treatment adherence [7] . Overall, the course of treatment for NTM infections usually lasts for more than 12 months. However, the severity and natural course of infections depend on the immunological status of the host. Long-term anti-NTM treatment maybe necessary among patient with incurable immunocompromised status. Disseminated MAC infections were very common in patients with advanced AIDS in developing countries before the widespread use of potent antiretroviral therapies [8] . Because disseminated NTM is common and life-threatening in people with advanced AIDS, mycobacterial antibiotic prophylaxis is recommended in patients with HIV infection and whose CD4 count is less than 50 cells/mm 3 [9] . NTM infections occur mostly in immunocompromised patients. Hence, it is difficult to diagnosis disseminated NTM infection in non-immunocompromised patients. In our reported case, a patient without evidence of immunocompromised status was initially considered to have lung cancer instead of disseminated NTM infection. Fig. 4 The presence of anti-IFN-γ autoantibodies measured by indirect ELISA. IFN-γ (2μg/ml, BD Bioscience) was coated in each wells; and serially diluted plasma samples from the patient and control samples (dilutions: 1:100, 1:500, and 1:2500) were added into wells. After washing, anti-IFN-γ autoantibodies were detected by anti-human IgG antibodies (The Jackson Laboratory) previous described [4] Fig. 5 Osteolytic lesion at sternum diminished gradually after the treatment Fig. 6 The size of osteolytic lesion decreased after the treatment
Anti-IFN-γ autoantibodies
Macrophages generate IL-12/23 that is stimulated by microbial components, such as lipopolysaccharides, and responses to intracellular infection. IFN-γ is synthesised by T cells and NK cells under IL-12/23 stimulation. In turn, IFN-γ can activate macrophages, which destroy intracellular microbes. IFN-γ/IL-12/23 axis plays a crucial role against intracellular infections, such as disseminated NTM infections, salmonellosis, other intramacrophagic bacterial infections, and reactivating latent varicella-zoster virus infection [3, 10] . Several studies have revealed the impact of IFN-γ/IL-12/23 axis defects. Kamijo et al. reported a study in which IFN-γ receptordeficient mice were vaccinated with Bacillus Calmette-Guerin. Tumoral necrosis factor-α (TNF-α), IL-1α, and IL-6 could not be produced after infection in the IFNreceptor-deficient mice. Subsequently, these mice could neither form granulation nor kill mycobacteria because of cell-media immunity defects [11] . Mendelian susceptibility to mycobacterial diseases (MSMD) is a term used to describe a group of patients who are susceptible to mycobacterial diseases because of primary immunodeficiency diseases, including a defect of the interferon-γ receptor [12] . Anti-IFN-γ autoantibodies have received increasing attention recently and have been associated with disseminated, recurrence, and refractory NTM infections. Patients with high titer of anti-IFN-γ autoantibodies are vulnerable to intracellular microbes in a way similar to MSMD. High titer of anti-IFN-γ autoantibodies are defined as detectable anti-IFN-γ autoantibodies in plasma diluted 1:5000 [13, 14] . Regardless, the origin of anti-IFN-γ autoantibodies and its mechanisms remain unclear. Cases of patients with disseminated NTM because of anti-IFN-γ autoantibodies were first reported in 2004 [15, 16] [10, 17] . In the aforementioned studies, examination for anti-IFN-γ autoantibodies suggested disseminated NTM infection in the patients without known immunological defect, especially in those of Asian origin. Recent studies have shown that treatment with rituximab could improve the prognosis of disseminated NTM infection with anti-IFN-γ autoantibodies. Rituximab is a monoclonal antibody against the B cell protein CD20. It is recognised as a key cornerstone to treat diffuse large B-cell lymphoma. Rituximab may improve the recovery of IFN-γ signalling by IFN-γ-induced STAT1 phosphorylation [14] . Although large randomised controlled trials to support this hypothesis are lacking, rituximab could be an option or rescue treatment for disseminated NTM infection in patients with anti-IFN-γ autoantibody.
We presented a case of disseminated NTM infection in a previously healthy Asian male with anti-IFN-γ autoantibody. Detection of anti-IFN-γ autoantibodies may help to identify the risk of NTM infection, particularly in people of Asian origin. To date, there are no established differences in the treatments available for patients with or without anti-IFN-γ autoantibodies. Due to patient's personal reasons, there was no serial data of titer of anti-IFN-γ autoantibodies in our case during treatment and clinical followup. However, disseminated NTM infection with anti-IFN-γ autoantibodies may indicate treatment failure and recurrent according to previous case reports. Rituximab may be considered as an optional treatment for refractory or recurrent NTM infection in patients with anti-IFN-γ autoantibody, although evidence to support this is currently lacking. 
